Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.
Upon completion of this activity, participants should be able to:
Integrating Recent Data When Selecting First-line Antiretroviral Therapy
What I Use and Why: Expert Strategies for Selecting the Best ART Regimen for Each Patient
Cardiovascular Disease in HIV-Infected Patients: Predict It and Prevent It
NCT02071082: Switch to EVG/COBI/FTC/TAF Maintains HIV and HBV Virologic Suppression Through Week 48 in Patients With HIV/HBV Coinfection on Stable ART
More Favorable Safety Profile, Similar Efficacy With First-line Doravirine Plus TDF/FTC vs Efavirenz Plus TDF/FTC
Clinical Care Options, LLC. All Rights Reserved.